RxDoctor Payments Data

Hani Salti, MD

Cardiovascular Disease · Vernon Hills, ILNPI 1285673988

Payments from drug & device makers

$3,090in general payments, 2019–2025

Across 122 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$805
  • Lantheus Medical Imaging, Inc.$297
  • Pfizer$257
  • E.r. Squibb & Sons, L.L.C.$213
  • Boston Scientific$204
  • Amarin Pharma, Inc.$200
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,090 in reported general payments places this provider in the 55th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$222,894
Medicare patients
1,365
Services billed
4,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban461$593,186
EntrestoSacubitril/Valsartan118$158,468
VascepaIcosapent Ethyl132$103,467
JardianceEmpagliflozin58$63,166
FarxigaDapagliflozin Propanediol34$45,375
Repatha SureclickEvolocumab53$36,880
XareltoRivaroxaban30$33,191
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide426$17,154
BrilintaTicagrelor14$15,300
Icosapent Ethyl49$12,680
Ranolazine ErRanolazine78$11,786
Atorvastatin Calcium1,105$10,761
Valsartan363$10,070
Ezetimibe286$9,470
Metoprolol Succinate486$8,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$257$593,186461 claims
NovartisEntresto$805$158,468118 claims
Boehringer IngelheimJardiance$118$63,16658 claims
AstraZenecaFarxiga, Brilinta$71$60,67548 claims
Kowa Pharmaceuticals America, Inc.Bystolic$23$5,07213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Vernon Hills

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →